Have you heard about the latest developments in cancer research? SOPHiA GENETICS $SOPH (-2,4%) has reached a significant milestone with its innovative applications for liquid biopsies. In a worldwide collaboration with 37 renowned institutions, including leading researchers, the MSK-ACCESS® application has been launched. This technology enables more accurate and faster cancer diagnosis.
Professor Umberto Malapelle from the University Federico II in Naples emphasizes how important these new applications are for his research. He sees SOPHiA GENETICS as a key partner in shaping the future of cancer research. Ross Muken, President of SOPHiA GENETICS, emphasizes the importance of this technology for improving healthcare worldwide.
With the adoption of MSK-ACCESS® by 34 of the 37 institutions, it is clear that SOPHiA GENETICS' technology represents a real advance in cancer diagnostics. What do you think about the role of technologies like this in medicine? 👍📈